Therapeutic Implications of the Cancer Stem Cell Hypothesis

Seminars in Radiation Oncology

Volumn 19, Issue 2, 2009, Pages 78-86

  Diehn, Maximilian ^a,c   Cho, Robert W ^b,c   Clarke, Michael F ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MONOCLONAL ANTIBODY; PARTHENOLIDE; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CELL ASSAY; CELL DIFFERENTIATION; CELL ISOLATION; CELL SUBPOPULATION; CELL TYPE; CLINICAL RESEARCH; CYTOTOXICITY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; NEOPLASM; NONHUMAN; ONCOGENE NEU; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 60949110035     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2008.11.002     Document Type: Review

References (69)

1. Deome K.B., Faulkin Jr. L.J., Bern H.A., et al. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res 19 (1959) 515-520
2. Kordon E.C., and Smith G.H. An entire functional mammary gland may comprise the progeny from a single cell. Development 125 (1998) 1921-1930
3. Tsai Y.C., Lu Y., Nichols P.W., et al. Contiguous patches of normal human mammary epithelium derived from a single stem cell: Implications for breast carcinogenesis. Cancer Res 56 (1996) 402-404
4. Shackleton M., Vaillant F., Simpson K.J., et al. Generation of a functional mammary gland from a single stem cell. Nature 439 (2006) 84-88
5. Stingl J., Eirew P., Ricketson I., et al. Purification and unique properties of mammary epithelial stem cells. Nature 439 (2006) 993-997
6. Bruce W.R., and Van Der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in Vivo. Nature 199 (1963) 79-80
7. Hewitt H.B., Blake E.R., and Walder A.S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 33 (1976) 241-259
8. Hill R.P., and Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 16 (1989) 513-518
9. Hamburger A.W., and Salmon S.E. Primary bioassay of human tumor stem cells. Science 197 (1977) 461-463
10. West C.M., Davidson S.E., and Hunter R.D. Evaluation of surviving fraction at 2 Gy as a potential prognostic factor for the radiotherapy of carcinoma of the cervix. Int J Radiat Biol 56 (1989) 761-765
11. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997) 730-737
12. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-648
13. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100 (2003) 3983-3988
14. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401
15. Collins A.T., Berry P.A., Hyde C., et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65 (2005) 10946-10951
16. Dalerba P., Dylla S.J., Park I.K., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104 (2007) 10158-10163
17. O'Brien C.A., Pollett A., et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 (2007) 106-110
18. Prince M.E., Sivanandan R., Kaczorowski A., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 104 (2007) 973-978
19. Li C., Heidt D.G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Res 67 (2007) 1030-1037
20. Hermann P.C., Huber S.L., Herrler T., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell. Stem Cells 1 (2007) 313-323
21. Yang Z.F., Ho D.W., Ng M.N., et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cells 13 (2008) 153-166
22. Reya T., Morrison S.J., Clarke M.F., et al. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
23. Dangles-Marie V., Pocard M., Richon S., et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: Comparison of success rate and cell line features. Cancer Res 67 (2007) 398-407
24. Ho M.M., Ng A.V., Lam S., et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67 (2007) 4827-4833
25. Patrawala L., Calhoun T., Schneider-Broussard R., et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res 65 (2005) 6207-6219
26. Todaro M., Alea M.P., Di Stefano A.B., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell. Stem Cells 1 (2007) 389-402
27. Dylla S.J., Beviglia L., Park I.K., et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE 3 (2008) e2428
28. Li X., Lewis M.T., Huang J., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100 (2008) 672-679
29. Ishikawa F., Yoshida S., Saito Y., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25 (2007) 1315-1321
30. Kobielak K., Stokes N., de la Cruz J., et al. Loss of a quiescent niche but not follicle stem cells in the absence of bone morphogenetic protein signaling. Proc Natl Acad Sci U S A 104 (2007) 10063-10068
31. Barker N., van Es J.H., Kuipers J., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449 (2007) 1003-1007
32. Hirschmann-Jax C., Foster A.E., Wulf G.G., et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101 (2004) 14228-14233
33. Dean M., Fojo T., and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 5 (2005) 275-284
34. Donnenberg V.S., and Donnenberg A.D. Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis. J Clin Pharmacol 45 (2005) 872-877
35. Ginestier C., Hur M.H., Charafe-Jauffret E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell. Stem Cells 1 (2007) 555-567
36. Easterday M.C., Dougherty J.D., Jackson R.L., et al. Neural progenitor genes. Germinal zone expression and analysis of genetic overlap in stem cell populations. Dev Biol 264 (2003) 309-322
37. Forsberg E.C., Prohaska S.S., Katzman S., et al. Differential expression of novel potential regulators in hematopoietic stem cells. PLoS Genet 1 (2005) e28
38. Park I.K., He Y., Lin F., et al. Differential gene expression profiling of adult murine hematopoietic stem cells. Blood 99 (2002) 488-498
39. Park I.K., Qian D., Kiel M., et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423 (2003) 302-305
40. Park I.-K., Klug C.A., Li K., et al. Molecular cloning and characterization of a novel regulator of G protein signaling from mouse hematopoietic stem cells. J Biol Chem 276 (2001) 915-923
41. Ponta H., Sherman L., and Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4 (2003) 33-45
42. Jin L., Hope K.J., Zhai Q., et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12 (2006) 1167-1174
43. Marhaba R., and Zoller M. CD44 in cancer progression: Adhesion, migration and growth regulation. J Mol Histol 35 (2004) 211-231
44. Cameron D.A., and Stein S. Drug insight: Intracellular inhibitors of HER2-Clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 5 (2008) 512-520
45. Dinh P., de Azambuja E., Cardoso F., et al. Facts and controversies in the use of trastuzumab in the adjuvant setting. Nat Clin Pract Oncol (2008)
46. Korkaya H., Paulson A., Iovino F., et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27 (2008) 6120-6130
47. Cho R., Wang X., Diehn M., et al. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 26 (2008) 364-371
48. Dontu G., Jackson K.W., McNicholas E., et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6 (2004) R605-R615
49. Liu S., Dontu G., Mantle I.D., et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66 (2006) 6063-6071
50. Dovey J.S., Zacharek S.J., Kim C.F., et al. Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc Natl Acad Sci U S A 105 (2008) 11857-11862
51. Leung C., Lingbeek M., Shakhova O., et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428 (2004) 337-341
52. Yilmaz O.H., Valdez R., Theisen B.K., et al. PTEN dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 (2006) 475-482
53. Lee J., Son M.J., Woolard K., et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cells 13 (2008) 69-80
54. Piccirillo S.G., Reynolds B.A., Zanetti N., et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444 (2006) 761-765
55. Guzman M.L., Rossi R.M., Karnischky L., et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105 (2005) 4163-4169
56. Liu R., Wang X., Chen G.Y., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356 (2007) 217-226
57. Fialkow P.J. Use of genetic markers to study cellular origin and development of tumors in human females. Adv Cancer Res 15 (1972) 191-226
58. Fialkow P.J. Stem cell origin of human myeloid blood cell neoplasms. Verh Dtsch Ges Pathol 74 (1990) 43-47
59. Fialkow P.J., Singer J.W., Adamson J.W., et al. Acute nonlymphocytic leukemia: Heterogeneity of stem cell origin. Blood 57 (1981) 1068-1073
60. Jamieson C.H., Ailles L.E., Dylla S.J., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351 (2004) 657-667
61. Krivtsov A.V., Twomey D.Z., Feng Z., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-Af 9. Nature 442 (2006) 818-822
62. Odoux C., Fohrer H., Hoppo T., et al. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 68 (2008) 6932-6941
63. Abratt R.P., Brune D., Dimopoulos M.A., et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 15 (2004) 1613-1621
64. Huff C.A., Matsui W., Smith B.D., et al. The paradox of response and survival in cancer therapeutics. Blood 107 (2006) 431-434
65. Rocha Lima C.M., Green M.R., Rotche R., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22 (2004) 3776-3783
66. Balic M., Lin H., Young L., et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12 (2006) 5615-5621
67. - phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10 (2008) R53
68. Horwitz K.B., Dye W.W., Harrell J.C., et al. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A 105 (2008) 5774-5779
69. Hart L.S., and El-Deiry W.S. Invincible, but not invisible: Imaging approaches toward in-vivo detection of cancer stem cells. J Clin Oncol 26 (2008) 2901-2910